Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback